Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients

References

• World Health Organization. Coronavirus disease (COVID-19) pandemic; 2020 Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed 420, 2020.
   Google Scholar
• VabretN, BrittonGJ, GruberC, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;6(52):910–941. doi:10.1016/j.immuni.2020.05.002
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention-Coronavirus (COVID-19); 2020 Available from: https://www.cdc.gov/coronavirus/2019-ncov/index.html. Accessed 413, 2020.
   Google Scholar
• SavarinoA, Di TraniL, DonatelliI, CaudaR, CassoneA. New insights into the antiviral effects of chloroquine. Lancet Infect Dis. 2006;6(2):67–69. doi:10.1016/S1473-3099(06)70361-916439323
   PubMed Web of Science ®Google Scholar
• VincentMJ, BergeronE, BenjannetS, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi:10.1186/1743-422X-2-6916115318
   PubMed Web of Science ®Google Scholar
• WangM, CaoR, ZhangL, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-032020029
   PubMed Web of Science ®Google Scholar
• DevauxCA, RolainJM, ColsonP, RaoultD. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55:105938. doi:10.1016/j.ijantimicag.2020.10593832171740
   PubMed Web of Science ®Google Scholar
• Chinese Clinical Trial Registry. Available from: http://www.chictr.org.cn/index.aspx. Accessed 530, 2020 Chinese.
   Google Scholar
• GaoJ, TianZ, YangX. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi:10.5582/bst.2020.0104732074550
   PubMed Web of Science ®Google Scholar
• CoppockK FDA announces two drugs given ‘compassionate use’ status in treating COVID-19; 2020 Available from: https://www.pharmacytimes.com/news/fda-announces-two-drugs-approved-for-compassionate-use-in-treating-covid-19. Accessed 319, 2020.
   Google Scholar
• Chinese National Health Committee. [Diagnosis and treatment of novel coronavirus pneumonia (trial version 7)]; 2020 Available from: http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml. Accessed 330, 2020 Chinese.
   Google Scholar
• BorbaM, ValF, SampaioVS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. doi:10.1001/jamanetworkopen.2020.8857
   PubMed Web of Science ®Google Scholar
• ZhouD, DaiSM, TongQ. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. Epub 2020 Mar 20
   Web of Science ®Google Scholar
• YaoX, YeF, ZhangM, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. Epub 2020 Mar 9.
   Web of Science ®Google Scholar
• GautretP, LagierJC, ParolaP, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. Epub 2020 Mar 20.
   Web of Science ®Google Scholar
• ChenZ, HuJ, ZhangZ, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv. 2020;2020–2023.
   Google Scholar
• ChenJ, LiuD, LiuL, et al. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215–219. Chinese.32391667
   PubMedGoogle Scholar
• TangW, CaoZ, HanM, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849. doi:10.1136/bmj.m184932409561
   PubMed Web of Science ®Google Scholar
• GelerisJ, SunY, PlattJ, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. Epub 2020 May 7.
   Web of Science ®Google Scholar
• World Health Organization. “Solidarity” clinical trial for COVID-19 treatments; 2020 Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments. Accessed 65, 2020.
   Google Scholar
• BoulwareDR, PullenMF, BangdiwalaAS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. Epub 2020 Jun 3.
   Web of Science ®Google Scholar
• FurutaY, GowenBB, TakahashiK, ShirakiK, SmeeDF, BarnardDL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446–454. doi:10.1016/j.antiviral.2013.09.01524084488
   PubMed Web of Science ®Google Scholar
• CaiQ, YangM, LiuD, et al. Experimental treatment with favipiravir for COVID-19: an Open-Label Control Study. Engineering (Beijing). Epub 2020 Mar 18.
   Google Scholar
• ChenC, ZhangY, HuangJ, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020;2020–2023.
   Google Scholar
• DuYX, ChenXP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. Epub 2020 Apr 4
   Web of Science ®Google Scholar
• NukoolkarnV, LeeVS, MalaisreeM, AruksakulwongO, HannongbuaS. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors. J Theor Biol. 2008;254(4):861–867. doi:10.1016/j.jtbi.2008.07.03018706430
   PubMed Web of Science ®Google Scholar
• LimJ, JeonS, ShinHY, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35(6):e79. doi:10.3346/jkms.2020.35.e7932056407
   PubMed Web of Science ®Google Scholar
• CaoB, WangY, WenD, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa200128232187464
   PubMed Web of Science ®Google Scholar
• CaoB, ZhangD, WangC. A trial of lopinavir-ritonavir in Covid-19. Reply. N Engl J Med. Epub 2020 May 5
   Web of Science ®Google Scholar
• BlaisingJ, PolyakSJ, PecheurEI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84–94. doi:10.1016/j.antiviral.2014.04.00624769245
   PubMed Web of Science ®Google Scholar
• WangZ, YangB, LiQ, WenL, ZhangR. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. Epub 2020 Mar 16
   Web of Science ®Google Scholar
• XuK, CaiH, ShenY, et al. [Management of corona virus disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):147–157. Chinese.32391658
   PubMedGoogle Scholar
• DengL, LiC, ZengQ, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. Epub 2020 Mar 11.
   Web of Science ®Google Scholar
• ZhuZ, LuZ, XuT, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21–e23. doi:10.1016/j.jinf.2020.03.06032283143
   PubMed Web of Science ®Google Scholar
• ZhangJN, WangWJ, PengB, et al. Potential of arbidol for post-exposure prophylaxis of COVID-19 transmission-a preliminary report of a retrospective cohort study. Curr Med Sci. 2020;1–6.32166659
   PubMed Web of Science ®Google Scholar
• StockmanLJ, BellamyR, GarnerP. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. doi:10.1371/journal.pmed.003034316968120
   PubMed Web of Science ®Google Scholar
• KainT, LindsayPJ, AdhikariN, ArabiYM, Van KerkhoveMD, FowlerRA. Pharmacologic treatments and supportive care for middle east respiratory syndrome. Emerg Infect Dis. 2020;26(6):1102–1112. doi:10.3201/eid2606.20003732213260
   PubMed Web of Science ®Google Scholar
• OmraniAS, SaadMM, BaigK, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095. doi:10.1016/S1473-3099(14)70920-X25278221
   PubMed Web of Science ®Google Scholar
• AlGM, AlghamdiKM, GhandooraY, et al. Treatment outcomes for patients with middle eastern respiratory syndrome coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis. 2016;16:174. doi:10.1186/s12879-016-1492-427097824
   PubMed Web of Science ®Google Scholar
• ShalhoubS, FarahatF, Al-JiffriA, et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat middle east respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70(7):2129–2132. doi:10.1093/jac/dkv08525900158
   PubMed Web of Science ®Google Scholar
• ZengYM, XuXL, HeXQ, et al. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol. Chin Med J (Engl). 2020;133(9):1132–1134. doi:10.1097/CM9.000000000000079032149772
   PubMed Web of Science ®Google Scholar
• IpAY, ArakawaT, SilversH, RansoneCM, NivenRW. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization. J Pharm Sci. 1995;84(10):1210–1214. doi:10.1002/jps.26008410138801336
   PubMed Web of Science ®Google Scholar
• WarrenTK, JordanR, LoMK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385. doi:10.1038/nature1718026934220
   PubMed Web of Science ®Google Scholar
• ElfikyA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477. doi:10.1016/j.lfs.2020.11747732119961
   PubMed Web of Science ®Google Scholar
• HolshueML, DeBoltC, LindquistS, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi:10.1056/NEJMoa200119132004427
   PubMed Web of Science ®Google Scholar
• GreinJ, OhmagariN, ShinD, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336. doi:10.1056/NEJMoa200701632275812
   PubMed Web of Science ®Google Scholar
• BeigelJH, TomashekKM, DoddLE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. Epub 2020 May 22.
   Google Scholar
• Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment; 2020 Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment. Accessed 526, 2020.
   Google Scholar
• UllbergS, LindquistNG, SjòstrandSE. Accumulation of chorio-retinotoxic drugs in the foetal eye. Nature. 1970;227(5264):1257–1258. doi:10.1038/2271257a05452818
   PubMed Web of Science ®Google Scholar
• SalmanS, BaiwogF, Page-SharpM, et al. Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling. Int J Antimicrob Agents. 2017;50(4):542–551. doi:10.1016/j.ijantimicag.2017.05.01128669839
   PubMed Web of Science ®Google Scholar
• DivalaTH, MungwiraRG, MawindoPM, et al. Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. Lancet Infect Dis. 2018;18(10):1097–1107. doi:10.1016/S1473-3099(18)30415-830195996
   PubMed Web of Science ®Google Scholar
• LallooDG, ShingadiaD, BellDJ, BeechingNJ, WhittyC, ChiodiniPL. UK malaria treatment guidelines 2016. J Infect. 2016;72(6):635–649. doi:10.1016/j.jinf.2016.02.00126880088
   PubMed Web of Science ®Google Scholar
• KlingerG, MoradY, WestallCA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet. 2001;358(9284):813–814. doi:10.1016/S0140-6736(01)06004-411564493
   PubMed Web of Science ®Google Scholar
• SciasciaS, HuntBJ, Talavera-GarciaE, LlisoG, KhamashtaMA, CuadradoMJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016;214(2):271–273. doi:10.1016/j.ajog.2015.09.078
   Web of Science ®Google Scholar
• Costedoat-ChalumeauN, AmouraZ, AymardG, et al. Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum. 2002;46(4):1123–1124. doi:10.1002/art.1015011953993
   PubMed Web of Science ®Google Scholar
• AVIGAN® (ファビピラビル錠) [prescribing information]. 富士フイルム富山化学株式会社; 2019 Japanese.
   Google Scholar
• PasleyMV, MartinezM, HermesA, D’AmicoR, NiliusA. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review. AIDS Rev. 2013;15(1):38–48.23449228
   PubMed Web of Science ®Google Scholar
• AIDSinfo. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. NGC. 2012;6(12):363–364.
   Google Scholar
• PattersonKB, DumondJB, PrinceHA, et al. Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr. 2013;63(1):51–58. doi:10.1097/QAI.0b013e31827fd47e23221983
   PubMed Web of Science ®Google Scholar
• KALETRA® (lopinavir and ritonavir) tablets and oral solution [prescribing information]. AbbVie Inc; 2019.
   Google Scholar
• MaasiltaP, HalmeM, MattsonK, CantellK. Pharmacokinetics of inhaled recombinant and natural alpha interferon. Lancet. 1991;337(8737):371. doi:10.1016/0140-6736(91)91009-J
   PubMed Web of Science ®Google Scholar
• GiosuèS, CasariniM, AmeglioF, AlemannoL, SaltiniC, BisettiA. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects. Eur Respir J. 1996;9(1):42–46. doi:10.1183/09031936.96.090100428834332
   PubMed Web of Science ®Google Scholar
• Fact sheet for health care providers: emergency use authorization (EUA) of remdesivir (GS-5734™); Available from: https://www.fda.gov/media/137566/download. Accessed 526, 2020.
   Google Scholar
• BulgakovaVA, PoromovAA, GrekovaAI, et al. [Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups]. Ter Arkh. 2017;89(1):62–71. Russian. doi:10.17116/terarkh201789162-71
   PubMed Web of Science ®Google Scholar
• ARALEN® (chloroquine phosphate) tablet [prescribing information]. Sanofi-aventis U.S. LLC; 2018.
   Google Scholar
• PLAQUENIL® (hydroxychloroquine sulfate) tablets [prescribing information]. Concordia Pharmaceuticals Inc; 2018.
   Google Scholar
• MadelainV, NguyenTH, OlivoA, et al. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet. 2016;55(8):907–923. doi:10.1007/s40262-015-0364-126798032
   PubMed Web of Science ®Google Scholar
• NyuntMM, LuY, El-GasimM, ParsonsTL, PettyBG, HendrixCW. Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine. Clin Pharmacol Ther. 2012;91(5):889–895. doi:10.1038/clpt.2011.32622472986
   PubMed Web of Science ®Google Scholar
• PengJZ, PulidoF, CausemakerSJ, et al. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Clin Pharmacol. 2006;46(3):265–274. doi:10.1177/009127000528485316490802
   PubMed Web of Science ®Google Scholar
• DengP, ZhongD, YuK, ZhangY, WangT, ChenX. Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother. 2013;57(4):1743–1755. doi:10.1128/AAC.02282-1223357765
   PubMed Web of Science ®Google Scholar
• Uptodate. Chloroquine: drug information. Available from: https://www.uptodate.com/contents/chloroquine-drug-information. Accessed 410, 2020.
   Google Scholar
• TailorR, ElaraoudI, GoodP, Hope-RossM, ScottRA. A case of severe hydroxychloroquine-induced retinal toxicity in a patient with recent onset of renal impairment: a review of the literature on the use of hydroxychloroquine in renal impairment. Case Rep Ophthalmol Med. 2012;2012:182747.23304587
   PubMedGoogle Scholar
• Manuosu® (arbidol hydrochloride) tablet [prescribing information]. Jiangsu Wuzhong Pharmaceutical group corporation; 2016.
   Google Scholar
• YangX, YuY, XuJ, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi:10.1016/S2213-2600(20)30079-532105632
   PubMed Web of Science ®Google Scholar
• PistolesiV, MorabitoS, Di MarioF, RegolistiG, CantarelliC, FiaccadoriE. A guide to understanding antimicrobial drug dosing in critically Ill patients on renal replacement therapy. Antimicrob Agents Chemother. 2019;63(8):. doi:10.1128/AAC.00583-19.
   PubMed Web of Science ®Google Scholar
• FaviéLM, MurkJL, MeijerA, NijstadAL, van MaarseveenEM, SikmaMA. Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza. Antivir Ther. 2018;23(5):457–461. doi:10.3851/IMP321029185991
   PubMed Web of Science ®Google Scholar
• MacLarenG, FisherD, BrodieD. Preparing for the most critically Ill Patients with COVID-19: the potential role of extracorporeal membrane oxygenation. JAMA. Epub 2020 Feb 19
   Web of Science ®Google Scholar
• ChengV, Abdul-AzizMH, RobertsJA, ShekarK. Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients. Expert Opin Drug Metab Toxicol. 2019;15(2):103–112. doi:10.1080/17425255.2019.156359630582435
   PubMed Web of Science ®Google Scholar
• GhaziSM, OgungbenroK, KosmidisC, et al. The effect of veno-venous ECMO on the pharmacokinetics of ritonavir, darunavir, tenofovir and lamivudine. J Crit Care. 2017;40:113–118. doi:10.1016/j.jcrc.2017.03.01028384599
   PubMed Web of Science ®Google Scholar
• WildschutED, AhsmanMJ, AllegaertK, MathotRA, TibboelD. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36(12):2109–2116. doi:10.1007/s00134-010-2041-z20862453
   PubMed Web of Science ®Google Scholar
• VankadariN. Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. Epub 2020 Apr 28
   Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: https://www.clinicaltrials.gov/. Accessed 531, 2020.
   Google Scholar